Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer

NCT02726503 | Completed Phase 2 DMC

• 2 other identifiers: TRIHN1504UMIN000020773
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 23

Brief Summary

The purpose of this phase Ⅱ study is to assess the efficacy and safety of lenvatinib for anaplastic thyroid cancer patients who are diagnosed as unresectable. The total duration of the study will be 30 months. All patients will start administration of lenvatinib within 1 week of enrollment and receive the study drug 24mg orally once daily at almost the same time. 1 cycle consists of 4 weeks. Treatment term starts on the day 1st of drug administration of cycle 1 and administration will be continued until patients meet withdrawal criteria. Safety and efficacy assesment will be conducted on a regular basis during the trial. Tumor evaluation will be conducted at 4weeks, 8 weeks, 12 weeks, 16 weeks and at every 8 weeks after the 16th week since initial administration. When study drug administration terminated,tests of the drug termination will be conducted within 7 days of withdrawal and final observation will be conducted at 30 days after the last dose. Survival survey will be conducted at follow-up term. After the termination of the study drug, survival follow up survey will be conducted every 12 weeks unless patients withdraw enrollment of this study.

Conditions

Anaplastic Thyroid Cancer

Keywords

anaplastic thyroid cancer, lenvatinib

Outcome Measures

Primary Outcomes (1)

• Overall Survival (OS)

  OS is defined as time frame from date of initial dose until date of death from any cause. Or until the last confirmed survival date, study cut-off date which ever comes first.

  up to 30 months

Secondary Outcomes (6)

• Progression-Free Survival (PFS)

  up to 30 months

• Best Overall Response (BOR)

  up to 30 months

• Objective Response Rate (ORR)

  up to 30 months

• Disease Control Rate (DCR)

  up to 30 months

• Clinical Benefit Rate (CBR)

  up to 30 months

Study Arms (1)

Treatment Arm

EXPERIMENTAL

Drug: Lenvatinib

Interventions

Lenvatinib DRUG

All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks. The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria.

Treatment Arm

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed as anaplastic thyroid cancer
• Unresectable disease
• Have measurable lesion defined by the RECIST version 1.1
• Have adequate organ function and meet following laboratory value:
• Bone marrow function test within 14 days prior to enrollment:
• neutrophil count\>=1.5 x 103/microL blood platelet count\>=10.0 x 104/microL hemoglobin amount\>=9.0 g/dL
• Liver function test within 14 days prior to enrollment:
• AST,ALT\<=3.0 x ULN(without liver metastatic) AST,ALT\<=5.0 x ULN(with liver metastatic) bilirubin\<=2.0 mg/dL
• Kidney function test within 14 days prior to enrollment:
• GFR estimation\>=50 ml/min/1.73 m2 GFR estimation calculated by following formula. Male:194 x(serum creatinine concentration)-1.094 x(Age)-0.287 Female:Male GFR estimation x 0.739
• Cardiac function test within 28 days prior to enrollment: 12-lead electrocardiogram: no clinically important abnormality as shown below: heart disease, severe arrhythmia etc.
• Regardless of usage of antihypertensive drug, systolic blood pressure \<=140 mm Hg and diastolic blood pressure \<=90 mm Hg (If already taking antihypertensive drug, must have capacity of further antihypertensive therapy.)
• ECOG performance status 0-2
• Ability to swallow oral medications
• Life expectancy greater than 8 weeks

You may not qualify if:

• Have complications or medical history of
• Complication of brain metastasis (Exclude if cured and in clinically stable condition for more than 1 month prior to screening.)
• Treatment required complication of systemic infectious disease
• Complication of pulmonary fibrosis or interstitial pneumonitis
• Medical history of clinically significant cardiovascular disease within 6 months of initial dose as: NYHA class above 2 leveled congestive heart failure, unstable angina, cardiac infarction or cardiac arrhythmia with paroxysmal or required treatment e) Uncontrollable complication of diabetes mellitus f) hemoptysis within 3 weeks of enrollment (blood volume of more than half of teaspoon) g) Medical history of hemorrhagic or thrombotic disease within 6 months of enrollment h) If proteinuria values above 2+ by urinary protein qualitative test, conduct 24-hour urine collection and the urine protein determined as 1g/24 hours or more. (can substitute to the ratio of proteinuria in morning urine/creatinine) i) Malabsorption at gastrointestinal tract and any of the complication diseases that investigator considers that will be affected to lenvatinib absorption j) Recent major surgery within 2 weeks (if needle biopsy within 1 week) of enrollment k) Drainage required celomic fluid stagnation
• Have history of lenvatinib administration
• Confirmed tumor invasion to the carotid arteries
• Have history of high dose external radiation therapy to cervical region, and irradiated tumor location close to the carotid arteries.
• Have any unresolved toxicity greater than 1 by CTCAE v4.0.
• Have active double cancer
• Female patients who are pregnant, lactating, breast feeding or have childbearing potential
• Psychiatric disorder and regarded by the investigator as inadequate for this study enrollment
• Confirmed as no resistance to any component of this drug
• Currently receiving other interventional clinical study treatment

Sponsors & Collaborators

• Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan: lead

Study Sites (23)

Nagoya University Hospital

Nagoya, Aichi-ken, 466-8560, Japan

Location

Fujita Health University Hospital

Toyoake, Aichi-ken, 470-1192, Japan

Location

IUHW Ichikawa Hospital

Ichikawa, Chiba, 272-0827, Japan

Location

National Cancer Center Hospital East

Kashiwa, Chiba, 277-8577, Japan

Location

Japanese Red Cross Narita Hospital

Narita, Chiba, 286-8523, Japan

Location

Kuma Hospital

Kobe, Hyōgo, 650-0011, Japan

Location

Kobe Univbersity Hospital

Kobe, Hyōgo, 650-0017, Japan

Location

University of Tsukuba Hospital

Tsukuba, Ibaraki, 305-8576, Japan

Location

Iwate Medical University Hospital

Morioka, Iwate, 020-8505, Japan

Location

Kitasato University Hospital

Sagamihara, Kanagawa, 252-0375, Japan

Location

Showa University Northern Yokohama Hospital

Yokohama, Kanagawa, 224-8503, Japan

Location

Kanagawa Cancer Center

Yokohama, Kanagawa, 241-8515, Japan

Location

Miyaghi Cancer Center

Natori-shi, Miyagi, 981-1293, Japan

Location

Tohoku University Hospital

Sendai, Miyagi, 980-8574, Japan

Location

Shinsyu University School of Medicine Department of Surgery

Matsumoto, Nagano, 390-8621, Japan

Location

Nara Hospital Kinki University Faculty of Medicine

Ikoma, Nara, 630-0293, Japan

Location

Nara Medical University

Kashihara, Nara, 634-8522, Japan

Location

Osaka Police Hospital

Osaka, Osaka, 543-0035, Japan

Location

Osaka City University Graduate School of Medicine and Faculty of Medicine

Osaka, Osaka, 545-8585, Japan

Location

Nippon Medical School Hospital

Bunkyo-ku, Tokyo, 113-8603, Japan

Location

The Cancer Institute Hospital of JFCR

Koto-ku, Tokyo, 135-8550, Japan

Location

Ito Hospital

Shibuya-ku, Tokyo, 150-8308, Japan

Location

Tokyo Medical University Hospital

Shinjuku-ku, Tokyo, 160-0023, Japan

Location

MeSH Terms

Conditions

Thyroid Carcinoma, Anaplastic

Interventions

lenvatinib

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Iwao Sugitani, M.D., Ph.D

  Graduate School of Medicine Nippon Medical School

  STUDY DIRECTOR

• Makoto Tahara, M.D., Ph.D

  National Cancer Center Hospital East

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 29, 2016
• First Posted: April 1, 2016
• Study Start: April 4, 2016
• Primary Completion: February 25, 2020
• Study Completion: March 20, 2020
• Last Updated: June 17, 2020

Record last verified: 2020-06

Locations

JP (23)